Last reviewed · How we verify
Eprotirome and ezetimibe
Eprotirome is a thyroid hormone receptor antagonist, and ezetimibe is a cholesterol absorption inhibitor.
Eprotirome is a thyroid hormone receptor antagonist, and ezetimibe is a cholesterol absorption inhibitor. Used for Hypercholesterolemia.
At a glance
| Generic name | Eprotirome and ezetimibe |
|---|---|
| Sponsor | Karo Bio AB |
| Drug class | Thyroid hormone receptor antagonist and cholesterol absorption inhibitor |
| Target | Thyroid hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Eprotirome works by blocking thyroid hormone receptors, which can help reduce thyroid hormone levels in the body. Ezetimibe, on the other hand, inhibits the absorption of cholesterol in the small intestine, leading to decreased cholesterol levels in the blood.
Approved indications
- Hypercholesterolemia
Common side effects
- Musculoskeletal pain
- Liver enzyme elevations
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eprotirome and ezetimibe CI brief — competitive landscape report
- Eprotirome and ezetimibe updates RSS · CI watch RSS
- Karo Bio AB portfolio CI